Tarsus Pharmaceuticals, Inc. (TARS)
NASDAQ: TARS · Real-Time Price · USD
62.02
+1.09 (1.78%)
At close: Apr 28, 2026, 4:00 PM EDT
62.09
+0.08 (0.12%)
After-hours: Apr 28, 2026, 4:10 PM EDT
Tarsus Pharmaceuticals Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Tarsus Pharmaceuticals stock have an average target of 89, with a low estimate of 51 and a high estimate of 105. The average target predicts an increase of 43.51% from the current stock price of 62.02.
Analyst Consensus: Buy
* Price targets were last updated on Feb 25, 2026.
Analyst Ratings
The average analyst rating for Tarsus Pharmaceuticals stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 2 |
| Buy | 3 | 4 | 4 | 4 | 4 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 9 | 9 | 9 | 9 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Maintains $95 → $105 | Buy | Maintains | $95 → $105 | +69.31% | Feb 25, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $87 → $90 | Strong Buy | Maintains | $87 → $90 | +45.13% | Feb 25, 2026 |
| Barclays | Barclays | Buy Initiates $100 | Buy | Initiates | $100 | +61.25% | Dec 9, 2025 |
| Mizuho | Mizuho | Buy Initiates $100 | Buy | Initiates | $100 | +61.25% | Nov 20, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $84 → $87 | Strong Buy | Maintains | $84 → $87 | +40.29% | Nov 5, 2025 |
Financial Forecast
Revenue This Year
706.04M
from 451.36M
Increased by 56.43%
Revenue Next Year
919.17M
from 706.04M
Increased by 30.19%
EPS This Year
-0.61
from -1.59
EPS Next Year
3.21
from -0.61
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 755.8M | 1.0B | ||||||
| Avg | 706.0M | 919.2M | ||||||
| Low | 668.1M | 833.0M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 67.4% | 47.0% | ||||||
| Avg | 56.4% | 30.2% | ||||||
| Low | 48.0% | 18.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 0.35 | 4.88 | ||||||
| Avg | -0.61 | 3.21 | ||||||
| Low | -0.88 | 1.91 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.